Antimalarial Sulfadoxine and Pyrimethamine Tablet 500+25mg Finished Medicine

• Customization: Available
• Application: Internal Medicine
• Usage Mode: For oral administration
• Model NO.: AMC12031
• State: Solid
• Shape: Tablet
• Type: Organic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Deliver Time: 30~60 Days
• Standard Available: Bp, Cp
• OEM/ODM: Support
• Transport Package: 50*3/Box
• Specification: 500+25mg
• Trademark: Medipharm, Shinepharm, OEM
• Origin: China
• HS Code: 3004909099
• Production Capacity: 1000000 Boxes/Month

Product Description

 

Product Description

l nephritis, BUN and serum creatinine elevation, toxic nephrosis with oliguria and anuria, and crystalluria.
Drug fever, chills, periarteritis nodosa and LE phenomenon have occurred.
Contra-indications:
Repeated prophylactic (prolonged) use in patients with severe renal or hepatic failure, or blood dyscrasias; documented megaloblastic anemia caused by folate deficiency; use in infants younger than 2 mo of age; prophylactic use in pregnancy at term and during lactation; hypersensitivity to pyrimethamine, sulfonamides, or any other ingredient of sulfadoxine/pyrimethamine.
Warning:
Fatalities associated with the administration of sulfonamides, although rare, have occurred due to severe reactions, including fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Fansidar (sulfadoxine and pyrimethamine) prophylactic regimen has been reported to cause leukopenia during a treatment of 2 months or longer. This leukopenia is generally mild and reversible.
Precautions:
Oral Sulfadoxine and Pyrimethamine has not been evaluated for the treatment of cerebral malaria or other severe manifestations of complicated malaria, including hyperparasitemia, pulmonary edema or renal failure. Patients with severe malaria are not candidates for oral therapy. In the event of recrudescent P. falciparum infections after treatment with Fansidar (sulfadoxine and pyrimethamine) or failure of chemoprophylaxis with Fansidar (sulfadoxine and pyrimethamine) , patients should be treated with a different blood schizonticide.
Sulfadoxine and Pyrimethamine should be given with caution to patients with impaired renal or hepatic function, to those with possible folate deficiency and to those with severe allergy or bronchial asthma. As with some sulfonamide drugs, in glucose-6-phosphate dehydrogenase-deficient individuals, hemolysis may occur. Urinalysis with microscopic examination and renal function tests should be performed during therapy of those patients who have impaired renal function. Excessive sun exposure should be avoided.
Storage instructions:
Store below 25ºC. Protect from moisture and light. Keep out of reach of children